Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969319 | 0.82 | PLAU (0.40) | PLAUPLATSLC8A1 | |
| SCHEMBL2649237 | 0.76 | ADORA3 (0.36) | NPSR1CNR2MMP1MMP13PLAU | |
| SCHEMBL16004927 | 0.69 | CCR5 (0.49) | CNR2 | |
| SCHEMBL27618200 | 0.67 | MMP1 (0.46) | NPSR1MMP1MMP13 | |
| SCHEMBL2333945 | 0.66 | ALDH1A1 (0.39) | NPSR1CNR2MMP1MMP13 | |
| SCHEMBL9988291 | 0.64 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL643982 | 0.64 | MMP1 (0.55) | MMP1MMP13 | |
| SCHEMBL14676239 | 0.63 | RECQL (0.47) | NPSR1CNR2MMP1MMP13 | |
| SCHEMBL12418064 | 0.62 | MMP1 (0.47) | NPSR1MMP1MMP13 | |
| SCHEMBL14680667 | 0.62 | CTSS (0.40) | NPSR1CNR2MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8178689-B2 | Tricyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | SARABU RAMAKANTH (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HAYNES NANCY-ELLEN | 2011-01-27 | — | — | US | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | NPSR1 4382/4885CNR2 3708/4885MMP1 1642/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | NPSR1 3628/4885CNR2 4299/4885MMP1 1272/4885 |
| US-20110021570-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | NPSR1 4382/4885CNR2 3708/4885MMP1 1642/4885 |
| US-20090264434-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | GCK, GCKR, PDXK | NPSR1 4397/4885CNR2 3936/4885MMP1 1682/4885 |
| US-20110313002-A1 | TRICYCLIC COMPOUNDS | GPR119, PC, GOT2 | NPSR1 1900/4885CNR2 262/4885MMP1 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.